Quick Answer
Taysha Gene Therapies, Inc. reported Total Revenue of $9.77 million for fiscal year 2025.
Taysha Gene Therapies, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.77M +17.3% |
$8.33M -46.1% |
$15.45M +517.5% |
$2.50M | — | — |
| Net Income | -$109.00M -22.1% |
-$89.30M +20.0% |
-$111.57M +32.8% |
-$166.01M +4.9% |
-$174.52M -190.8% |
-$60.01M |
| Diluted EPS | -$0.34 +5.6% |
-$0.36 +62.5% |
-$0.96 +74.6% |
-$3.78 +18.5% |
-$4.64 | — |
| Total Assets | $343.32M +114.1% |
$160.36M -7.2% |
$172.73M +36.8% |
$126.28M -41.0% |
$213.96M -17.4% |
$258.88M +1725773.3% |
| Cash and Equivalents | $319.77M +130.0% |
$139.04M -3.4% |
$143.94M +63.8% |
$87.88M -41.1% |
$149.10M -40.7% |
$251.25M |
| Long-Term Debt | $50.11M +14.0% |
$43.94M +8.5% |
$40.51M +6.7% |
$37.97M +2.1% |
$37.19M | — |
| Stockholders Equity | $246.94M +245.2% |
$71.53M -4.6% |
$74.94M +7796.4% |
$949.0K -99.0% |
$95.38M -62.0% |
$251.30M |
| R&D Expense | $86.40M +30.9% |
$66.00M +16.2% |
$56.78M -37.7% |
$91.17M -30.9% |
$131.94M +313.7% |
$31.89M |
| Operating Income | -$110.50M -20.8% |
-$91.46M -26.3% |
-$72.44M +55.4% |
-$162.45M +6.2% |
-$173.27M -302.9% |
-$43.00M |
| Shares Outstanding | 285.05M +39.1% |
204.94M +9.6% |
186.96M +195.8% |
63.21M +64.3% |
38.47M +1.9% |
37.76M +246.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$32.73M | -28.2% | -21.8% |
| Diluted EPS | September 30, 2025 | -$0.09 | +10.0% | +0.0% |
| Total Assets | September 30, 2025 | $316.55M | +75.7% | -5.0% |
| Cash and Equivalents | September 30, 2025 | $297.34M | +88.6% | -4.9% |
| Long-Term Debt | September 30, 2025 | $50.85M | +18.3% | +23.9% |
| Stockholders Equity | September 30, 2025 | $218.99M | +146.6% | -12.0% |
| R&D Expense | September 30, 2025 | $25.75M | +72.3% | +27.8% |
| Operating Income | September 30, 2025 | -$34.02M | -31.4% | -27.2% |
| Shares Outstanding | September 30, 2025 | 273.92M | +33.7% | +0.4% |
- Taysha Gene Therapies, Inc. reported Total Revenue of $9.77 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +17.3% in Total Revenue compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Net Income of -$109.00 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed a decrease of -22.1% in Net Income compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +5.6% in Diluted EPS compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Total Assets of $343.32 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +114.1% in Total Assets compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Cash and Equivalents of $319.77 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +130.0% in Cash and Equivalents compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Long-Term Debt of $50.11 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +14.0% in Long-Term Debt compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Stockholders Equity of $246.94 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +245.2% in Stockholders Equity compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported R&D Expense of $86.40 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +30.9% in R&D Expense compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Operating Income of -$110.50 million for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed a decrease of -20.8% in Operating Income compared to the prior fiscal year.
- Taysha Gene Therapies, Inc. reported Shares Outstanding of 285.05 million shares for fiscal year 2025.
- Taysha Gene Therapies, Inc. showed an increase of +39.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: